^
Association details:
| Biomarker: | IDH1 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | daporinad (APO866) (Nicotinamide phosphoribosyltransferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma
Excerpt:
Intrahepatic cholangiocarcinoma (ICC) is an aggressive liver bile duct malignancy exhibiting frequent isocitrate dehydrogenase (IDH1/IDH2) mutations....including the BCL-2 inhibitor, ABT-199, and the NAMPT inhibitor, FK866, which were observed to have enhanced activity against IDHm leukemia and glioma, respectively.
DOI:
10.1158/2159-8290.CD-15-1442
